Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

pantoprazole

This page shows the latest pantoprazole news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

The generic medicines to be included in the portfolio are Amoxicillin, Ceftriaxone, Clarithromycin, Colchicine, Dexamethasone, Dobutamine, Fluconazole, Heparin, Levofloxacin, Loperamide, Pantoprazole, Prednisone, Prednisolone, Salbutamol and

Latest news

  • Pfizer settles US Protonix lawsuit for $785m Pfizer settles US Protonix lawsuit for $785m

    over-charged Medicaid for Protonix (pantoprazole), failing to offer the federal government the same discounts it was offering to private customers.

  • Pfizer 2014 guidance threatened by Celebrex competition Pfizer 2014 guidance threatened by Celebrex competition

    The early onset of generic competition to Celebrex comes after a torrid time for Pfizer in terms of patent losses, with cholesterol lowerer Lipitor (atorvastatin), gastrointestinal medicine Protonix (pantoprazole), Viagra (sildenafil)

  • Teva defends Copaxone from Dutch patent challenge Teva defends Copaxone from Dutch patent challenge

    Maintaining Copaxone revenues is particularly important for Teva after it was ordered to pay $1.6bn in compensation to Pfizer and Takeda for infirming the patent on their Protonix (pantoprazole) gastrointestinal

  • Takeda expands Latin American footprint

    These will be ulcer treatments Zurcal (pantoprazole) and Riopan (Magaldrate Dimeticone), the anti-inflammatory Faktu (Policresulen, Cinchocaine hydrochloride) and Albothyl (Policresulen), a gynaecology product.

  • Pfizer sales dip as net income surges in Q2 Pfizer sales dip as net income surges in Q2

    from the spin-out of Zoetis and a litigation settlement with Teva and Sun Pharmaceutical Industries for patent infringement of Protonix (pantoprazole) fell 5 per cent.

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2013 Pharma deals during June 2013

    Top of the table is the patent settlement between Pfizer/ Takeda and Teva/ Sun Pharmaceutical for the launch of generic versions of Protonix (the proton pump inhibitor, pantoprazole) in 2007 ahead

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    For Nycomed this meant loss of exclusivity (LOE) on its blockbuster gastroinestinal drug pantoprazole and the consequent need to reorganise its business.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The 17th World Congress on Controversies in Neurology
This year, there was a focus on the rare disease neuromyelitis optica spectrum disorder that strikes suddenly and mainly impacts women...
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Tuberculosis – why it remains a major global public health challenge
Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...

Quick links